4D Molecular Therapeutics logo
4D Molecular Therapeutics
FDMT | NASDAQ
Chart Builder DCF Calculator
$11.29
-$0.94 (-7.69%)
At close: Nov 16, 2026, 4:00 PM ET
$11.29
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

4D Molecular Therapeutics Company Profile

Company profile explained

Company Profile

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

Key Executives

Name Position
David H. Kirn Co-Founder, President, CEO & Director
Scott Bizily Chief Legal Officer & Corporate Secretary
An Song Chief Translational Medicine Advisor
Fariborz Kamal Chief Technical Advisor
John F. Milligan Executive Chairman
Julian Pei Head of Investor Relations & Corporate Finance
Katy Barglow Chief Technical Officer
Kristian Humer CFO and Principal Financial & Accounting Officer
Noriyuki Kasahara Chief Scientific Advisor
Theresa Janke Co-Founder & Chief of Staff

Latest SEC Filings

Date Type Title
Oct 20, 2026 4 Filing
Oct 07, 2026 4 Filing
Sep 28, 2026 8-K Current Report
Sep 22, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 03, 2026 4 Filing
Aug 21, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 13, 2026 10-Q Quarterly Report
Aug 13, 2026 8-K Current Report
View All SEC Filings ➞
4D Molecular Therapeutics
4D Molecular Therapeutics logo
Country United States
IPO Date Dec 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 196
CEO David H. Kirn

Contact Details

5858 Horton Street EmeryVille, California 94608 United States

Stock Details

Ticker Symbol FDMT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001650648
CUSIP Number 35104E100
ISIN Number US35104E1001
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.